Increasing incidence of non-Hodgkin's lymphoma in Canada, 1970-1996: age-period-cohort analysis.

Abstract:

:Previous studies have shown that the incidence of non-Hodgkin's lymphoma (NHL) has increased in many parts of the world in recent decades. Using data obtained from the Canadian Cancer Registry, the present study examined time trends in NHL incidence in Canada between 1970 and 1996 and the effects of age, period of diagnosis and birth cohort on incidence patterns for each sex separately. Results showed that overall age-adjusted incidence rates increased substantially, from 7.3 and 5.2 per 100,000 in 1970-1971 to 14.0 and 10.0 per 100,000 in 1995-1996 in males and females, respectively. Diffuse lymphoma was the major histological subtype, accounting for approximately 76% of NHL cases over the 27-year period. The data suggest that period effects have played a major role, although birth cohort effects may also have been involved. Sex-specific patterns of the incidence were similar over the time period of diagnosis but were distinct among recent birth cohorts. In conclusion, there is in fact a marked increase in NHL in Canada which cannot be explained in terms of improvements in diagnosis, changes in NHL classification and the increase in AIDS-associated NHL alone. The birth cohort effect in NHL suggests that changes in risk factors may have contributed to the observed increase.

journal_name

Hematol Oncol

journal_title

Hematological oncology

authors

Liu S,Semenciw R,Mao Y

doi

10.1002/hon.703

subject

Has Abstract

pub_date

2003-06-01 00:00:00

pages

57-66

issue

2

eissn

0278-0232

issn

1099-1069

journal_volume

21

pub_type

杂志文章
  • Rare mature B-cell lymphomas in children and adolescents.

    abstract::Pediatric-type follicular lymphoma (PTFL), pediatric nodal marginal zone lymphoma (pnMZL), and large B-cell lymphoma (LBCL) with IRF4 rearrangement have been introduced into the current World Health Organization (WHO) classification. They account for 5% to 10% of mature B-cell lymphomas in children and adolescents. Bo...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/hon.2585

    authors: Woessmann W,Quintanilla-Martinez L

    更新日期:2019-06-01 00:00:00

  • Long-term results of treatment of patients with follicular lymphomas.

    abstract::The management of patients with follicular lymphoma is controversial, particularly in those with follicular small cleaved cell (FSCC) or nodular poorly differentiated lymphoma (NPDL). Some advocate no treatment until symptoms arise, while others prefer to treat with intensive combination regimens and others with singl...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900050207

    authors: Kalter S,Holmes L,Cabanillas F

    更新日期:1987-04-01 00:00:00

  • A simple, non-invasive method of assessing the acute hemodynamic effects of doxorubicin.

    abstract::Left ventricular stroke distance was measured by Doppler ultrasound in 10 doxorubicin-treated and 10 control patients. Measurements were made 10 min, 2 h and 4 h after drug administration. Stroke distance (a linear analogue of stroke volume) increased significantly from 12.6 cm (S.D. 2.7) before and 12.5 cm (S.D. 2.7)...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900090107

    authors: Clive S,Dawson A,Bennett B,Rawles J

    更新日期:1991-01-01 00:00:00

  • Conventional and high-dose daunorubicin and idarubicin in acute myeloid leukaemia remission induction treatment: a mixed treatment comparison meta-analysis of 7258 patients.

    abstract::Previous meta-analyses suggested that acute myeloid leukaemia induction regimens containing idarubicin (IDA) or high-dose daunorubicin (HDD) induce higher rates of complete remission (CR) than conventional-dose daunorubicin (CDD), with a possible benefit in overall survival. However, robust comparisons between these r...

    journal_title:Hematological oncology

    pub_type: 杂志文章,meta分析

    doi:10.1002/hon.2173

    authors: Sekine L,Morais VD,Lima KM,Onsten TG,Ziegelmann PK,Ribeiro RA

    更新日期:2015-12-01 00:00:00

  • In vitro maturation is a viable option for urgent fertility preservation in young women with hematological conditions.

    abstract::Fertility preservation embraces different techniques developed to improve young women chances of becoming mothers after healing. Among them, in vitro maturation (IVM) procedure is based on oocyte retrieval without any gonadotropin treatment, feasible under locoregional or local anesthesia, with very low operative comp...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2724

    authors: Sonigo C,Bajeux J,Boubaya M,Eustache F,Sifer C,Lévy V,Grynberg M,Sermondade N

    更新日期:2020-10-01 00:00:00

  • Detection rate of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with marginal zone lymphoma of MALT type: a meta-analysis.

    abstract::The aim of this article is to meta-analyse published data about the detection rate (DR) of fluorine-18-fluorodeoxyglucose ((18) F-FDG) positron emission tomography (PET) and PET/computed tomography (CT) in the evaluation of patients with marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT). A compreh...

    journal_title:Hematological oncology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1002/hon.2152

    authors: Treglia G,Zucca E,Sadeghi R,Cavalli F,Giovanella L,Ceriani L

    更新日期:2015-09-01 00:00:00

  • Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program.

    abstract::Because of the rarity of the disease, randomized clinical trials for multicentric Castleman disease (MCD) remain a challenge and, as a consequence, there is no established standard of care. Siltuximab is a chimeric immunoglobulin G1κ monoclonal antibody against human IL-6 which was recently approved by FDA. Eligible p...

    journal_title:Hematological oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1002/hon.2532

    authors: Tonialini L,Bonfichi M,Ferrero S,Malipiero G,Nozza A,Argnani L,Zinzani PL

    更新日期:2018-10-01 00:00:00

  • Prognosis in low grade non-Hodgkin's lymphoma: relevance of the number of sites involved, absolute lymphocyte count and serum immunoglobulin level.

    abstract::Eighty-eight patients with low grade non-Hodgkin's lymphoma were followed for a median period of 63 months. Sixty-eight per cent of the group were centrocytic/centroblastic B cell lymphomas by the updated Kiel classification. Fifty-one (58 per cent) of the patients were stage IV by the Ann Arbor classification. In 18 ...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900120104

    authors: Parker D,Alison DL,Barnard DL,Child JA,Dovey G,Farish J,Norfolk DR,O'Brien CJ,Parapia LA,Sharp J

    更新日期:1994-01-01 00:00:00

  • Acute myeloid leukaemia: expression of MYC protein and its association with cytogenetic risk profile and overall survival.

    abstract::Acute myeloid leukaemia (AML) is a clinically aggressive disease with marked genetic heterogeneity. Cytogenetic abnormalities provide the basis for risk stratification into clinically favourable, intermediate, and unfavourable groups. There are additional genetic mutations, which further influence the prognosis of pat...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2279

    authors: Mughal MK,Akhter A,Street L,Pournazari P,Shabani-Rad MT,Mansoor A

    更新日期:2017-09-01 00:00:00

  • Antisense therapy for lymphomas.

    abstract::The potential ability of antisense oligonucleotides to downregulate the expression of oncogenes involved in lymphoma, with minimal toxicity can be achieved. The possibility of combining antisense therapy such as BCL-2 antisense with chemotherapy will probably provide an interesting means of overcoming tumour cell resi...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/(sici)1099-1069(199702)15:1<3::aid-hon583>

    authors: Cotter FE

    更新日期:1997-02-01 00:00:00

  • Follicular lymphoma: Update on management and emerging therapies at the dawn of the new decade.

    abstract::Follicular lymphoma is the most common indolent non-Hodgkin lymphoma. Survival has improved over the last several decades, mainly because of the incorporation of the anti-CD20 antibody rituximab into preexisting or rediscovered agents. The disease has a relapsing and remitting pattern, coupled with a risk of transform...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/hon.2711

    authors: Apostolidis J,Mokhtar N,Al Omari R,Darweesh M,Al Hashmi H

    更新日期:2020-08-01 00:00:00

  • Residual mediastinal widening following therapy in Hodgkin's disease.

    abstract::The chest radiograms (CXR) of 102 patients with Hodgkin's disease presenting with mediastinal involvement at diagnosis were reviewed to assess the incidence and relevance of residual mediastinal abnormalities after therapy. All patients had completed planned treatment and had no evidence of persisting extramediastinum...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900080303

    authors: Orlandi E,Lazzarino M,Brusamolino E,Caldera D,Morra E,Dore R,Di Giulio G,Bernasconi C

    更新日期:1990-05-01 00:00:00

  • Intravascular lymphoma: a neoplasm of 'homeless' lymphocytes?

    abstract::Intravascular lymphoma (IVL) is an extremely rare form of non-Hodgkin lymphoma characterized by almost exclusive growth of neoplastic lymphocytes within blood vessel lumen. IVL is morphologically characterized in most instances by large cells with B-cell lineage. IVL is an aggressive and usually disseminated disease t...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/hon.776

    authors: Ponzoni M,Ferreri AJ

    更新日期:2006-09-01 00:00:00

  • Hodgkin's cell lines: characteristics and possible pathogenetic implications.

    abstract::In the last four years we established five long term cultures from tumor material of Hodgkin's disease. The in vitro cells have malignant characteristics and represent the in vivo H- and SR-cells. Common immunological, functional and morphological assays did not characterize the in vitro cells to be a known cell type ...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900010204

    authors: Diehl V,Burrichter H,Schaadt M,Kirchner HH,Fonatsch C,Stein H,Gerdes J,Heit W,Ziegler A

    更新日期:1983-04-01 00:00:00

  • Tumour burden at diagnosis as the main clinical predictor of cell resistance in patients with early stage, favourable Hodgkin lymphoma treated with VBM chemotherapy plus radiotherapy.

    abstract::We verified whether early resistance to treatment can be predicted in a subset of patients with very favourable, early stage Hodgkin lymphoma, treated with VBM (vinblastine, bleomycin and methotrexate) chemotherapy and involved-field radiotherapy, an effective combination with very low early and late toxicity. The rel...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2035

    authors: Gobbi PG,Bergonzi M,Bassi E,Merli F,Coriani C,Federico M

    更新日期:2013-09-01 00:00:00

  • Pooled analysis of the reports of pomalidomide after failure of lenalidomide and (or) bortezomib for multiple myeloma.

    abstract::The use of pomalidomide after lenalidomide and (or) bortezomib failure in patients with multiple myeloma is not clearly clarified in clinical practice. We sought to compile the available clinical reports to better understand the effectiveness of pomalidomide after failure of lenalidomide and (or) bortezomib. We search...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/hon.2192

    authors: Sheng Z,Liu G

    更新日期:2016-06-01 00:00:00

  • A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha-2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5)-AGMT

    abstract::The goal of current management of patients with chronic phase chronic myeloid leukemia (CML) is to reach treatment-free remission with sustained deep molecular remission (DMR) being the prerequisite therefor. Second-generation tyrosine kinase inhibitors can induce deeper and faster remission than imatinib, but are oft...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2786

    authors: Heibl S,Buxhofer-Ausch V,Schmidt S,Webersinke G,Lion T,Piringer G,Kuehr T,Wolf D,Melchardt T,Greil R,Thaler J

    更新日期:2020-12-01 00:00:00

  • Detection and monitoring of clonality in peripheral blood and bone marrow of patients with B-cell lymphoproliferative disorders.

    abstract::Bone marrow (BM) is accepted as the tissue of choice for the detection of monoclonal populations in leukemias and lymphomas; however, obtaining BM can be painful and traumatic for the patients. Although it is possible to detect clonality in peripheral blood (PB) samples, there are no reports comparing the results obse...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.701

    authors: Leal E,Esparza-Flores MA,López-Guido B,Aguilar-Luna C,Aguilar-López L,Jaloma-Cruz AR,Medina C,Barros-Núñez P

    更新日期:2003-03-01 00:00:00

  • Cytogenetics and molecular genetics of childhood leukemia.

    abstract::Childhood leukemia is the commonest form of childhood cancer and represents clonal proliferation of transformed hemopoietic cells as a result of genetic changes. Molecular characterization of these changes, in particular chromosomal translocations, has yielded a wealth of information on the mechanisms of leukemogenesi...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/(sici)1099-1069(199909)17:3<91::aid-hon643

    authors: Ma SK,Wan TS,Chan LC

    更新日期:1999-09-01 00:00:00

  • Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.

    abstract::The objective of this research was to characterize the venetoclax exposure-efficacy and exposure-safety relationships and determine its optimal dose in elderly patients with newly diagnosed acute myeloid leukemia (AML) receiving venetoclax in combination with low intensity therapies (hypomethylating agent [HMA; azacit...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2646

    authors: Agarwal S,Gopalakrishnan S,Mensing S,Potluri J,Hayslip J,Kirschbrown W,Friedel A,Menon R,Salem AH

    更新日期:2019-10-01 00:00:00

  • A review of the therapeutic agents used in the management of polycythaemia vera.

    abstract::The acquired clonal disorder Polycythaemia Vera leads to increased erythropoiesis, myelopoiesis and megakaryopoeisis. These anomalies result in an increased incidence of thromboembolic events, transformation to acute leukaemia and myelofibrosis. Treatments which aim to reduce the event rate may increase anaemia but ma...

    journal_title:Hematological oncology

    pub_type: 杂志文章,评审

    doi:10.1002/hon.809

    authors: McMullin MF

    更新日期:2007-06-01 00:00:00

  • Primary mediastinal large cell lymphoma (PMBL): frontline treatment with autologous stem cell transplantation (ASCT). The GEL-TAMO experience.

    abstract::Given the excellent results obtained with present new induction regimens in PMBL, the role of frontline ASCT is controversial. We present 71 patients with PMBL receiving induction chemotherapy, followed by ASCT as frontline therapy from the GEL-TAMO registry. Most patients presented with high-risk clinical features. A...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.858

    authors: Rodríguez J,Conde E,Gutiérrez A,García JC,Lahuerta JJ,Varela MR,Pérez C,Albo C,Caballero MD

    更新日期:2008-09-01 00:00:00

  • A pilot study of ChlOPhEPP-B--a weekly regimen for patients with untreated advanced or recurrent Hodgkin's disease.

    abstract::Twenty-five patients with either previously untreated advanced Hodgkin's disease (HD) or with relapsed disease were treated with an intensive weekly chemotherapy regimen (ChlOPhEPP-B) in which the myelosuppressive combinations of epirubicin and chlorambucil, and procarbazine and etoposide alternated at two-week interv...

    journal_title:Hematological oncology

    pub_type: 临床试验,杂志文章

    doi:10.1002/hon.2900100604

    authors: Smith GM,Wright D,Child JA,Simmons AV,Norfolk DR,Barnard DL,Parker D,Parapia L

    更新日期:1992-11-01 00:00:00

  • Rearrangement of human T cell receptor beta and gamma chain genes in adult T cell leukemia/lymphoma.

    abstract::We studied rearrangement of human T cell receptor genes (TCR) of C beta, C gamma, V gamma and J gamma in 34 cases of adult T cell leukemia/lymphoma (ATLL), consisting of 29 cases with monoclonally integrated HTLV-I proviral DNA (ATLL-W) and five without monoclonal integration (ATLL-O), in comparison with 12 cases of o...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900080207

    authors: Ohshima K,Yoshida T,Kikuchi M,Masuda Y,Kimura N,Satoh H

    更新日期:1990-03-01 00:00:00

  • Intensive retreatment of adults and children with acute lymphoblastic leukemia.

    abstract::Twenty-three patients (16 adults) failing their first or subsequent (n = 8) intensive treatment for de novo acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia lymphoid blast phase (n = 2) were managed with protocol POG 8201, originally introduced in relapsed ALL of childhood. In this programme, a four-dru...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900100206

    authors: Bassan R,Cornelli PE,Battista R,Terzi F,Buelli M,Rambaldi A,Viero P,D'Emilio A,Dini E,Barbui T

    更新日期:1992-03-01 00:00:00

  • Large cell lymphoma with initial presentation in the bone marrow.

    abstract::This report describes 14 cases of large cell lymphoma with initial presentation as marrow involvement in the absence of peripheral lymphadenopathy. The disease affected mainly the middle-aged and elderly, with male predominance. Most patients presented with swinging fever and peripheral blood cytopenia. Reactive hemop...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2900100504

    authors: Wong KF,Chan JK,Ng CS,Chu YC,Li LP,Chan CH

    更新日期:1992-09-01 00:00:00

  • Extranodal lymphomas in the public health system in Chile: Analysis of 1251 patients from the National Adult Cancer Program.

    abstract::The aim of the study was to describe the clinical and epidemiological characteristics, anatomic and histologic distribution, and treatment results of extranodal lymphomas (ENLs), diagnosed and treated in the public health system in Chile. We included patients with ENL diagnosed from 1998 to 2014, in 17 cancer centers,...

    journal_title:Hematological oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1002/hon.2547

    authors: Peña C,Russo M,Martinez V,Cabrera ME

    更新日期:2019-02-01 00:00:00

  • Retinoblastoma protein and Epstein-Barr virus (EBV) expression in South African Hodgkin's disease.

    abstract::The aim of this study was to explore the expression of retinoblastoma protein and EBV status in a cohort of cases of Hodgkin's disease from South Africa. Seventy one cases of Hodgkin's disease were accessed over a 6-year period and were classified according to the Rye Classification. Relevant sections were stained wit...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/(sici)1099-1069(199711)15:4<191::aid-hon61

    authors: Chetty R,Bickhoo A

    更新日期:1997-11-01 00:00:00

  • Regulation of the expression of MHC class I and II by class II transactivator (CIITA) in hematopoietic cells.

    abstract::In order to develop an effective immunotherapy for hematological malignancies, we investigated the applicability of class II transactivator (CIITA), which had been demonstrated to regulate the expression of MHC class II (MHC-II) by assembling the transcription factors of MHC-II molecules, for immunotherapy by potentia...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/(sici)1099-1069(199912)17:4<149::aid-hon64

    authors: Liu A,Takahashi M,Toba K,Zheng Z,Hashimoto S,Nikkuni K,Furukawa T,Koike T,Aizawa Y

    更新日期:1999-12-01 00:00:00

  • Severe retinopathy following radiation therapy with a moderate dose for orbital mucosa-associated lymphoid tissue lymphoma.

    abstract::Mucosa-associated lymphoid tissue (MALT) lymphoma is a radiosensitive malignancy. We report on a case of severe retinopathy following radiation therapy with a moderate dose for orbital MALT lymphoma. A 69-year-old woman with orbital MALT lymphoma received definitive radiation therapy with a total dose of 36 Gy in 18 f...

    journal_title:Hematological oncology

    pub_type: 杂志文章

    doi:10.1002/hon.2124

    authors: Hata M,Kaneko A,Tomita N,Inoue T

    更新日期:2014-12-01 00:00:00